Thelansis

  Fetomaternal alloimmune thrombocytopenia (FMAIT) arises when a woman develops antibodies against fetal platelet antigens inherited from the father, which are absent on the mother's platelets. This condition results in fetal thrombocytopenia (platelet count < 150,000/μL). While most cases manifest mildly with widespread petechiae and skin lesions, severe instances may lead to intracranial hemorrhage (ICH), potentially causing death or long-term disability. Unlike erythrocyte alloimmunization, FMAIT can occur in first pregnancies, often recurring with increased severity in subsequent pregnancies. It is the primary cause of severe neonatal thrombocytopenia and should not be confused with autoimmune thrombocytopenia, where both mother and fetus are affected by maternal autoantibodies. Diagnosing FMAIT presents two significant challenges. Firstly, some patients may possess uncommon antiplatelet antibodies, necessitating additional testing beyond initial checks for human platelet ...